JP2022533971A5 - - Google Patents
Info
- Publication number
- JP2022533971A5 JP2022533971A5 JP2021568611A JP2021568611A JP2022533971A5 JP 2022533971 A5 JP2022533971 A5 JP 2022533971A5 JP 2021568611 A JP2021568611 A JP 2021568611A JP 2021568611 A JP2021568611 A JP 2021568611A JP 2022533971 A5 JP2022533971 A5 JP 2022533971A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025062046A JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848420P | 2019-05-15 | 2019-05-15 | |
| US62/848,420 | 2019-05-15 | ||
| PCT/US2020/032941 WO2020232274A1 (en) | 2019-05-15 | 2020-05-14 | Ketamine formulation for subcutaneous injection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062046A Division JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533971A JP2022533971A (ja) | 2022-07-27 |
| JP2022533971A5 true JP2022533971A5 (https=) | 2023-05-23 |
| JPWO2020232274A5 JPWO2020232274A5 (https=) | 2023-05-23 |
Family
ID=73230954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568611A Pending JP2022533971A (ja) | 2019-05-15 | 2020-05-14 | 皮下注射のためのケタミン製剤 |
| JP2025062046A Pending JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062046A Pending JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10973780B2 (https=) |
| EP (1) | EP3968979A4 (https=) |
| JP (2) | JP2022533971A (https=) |
| CN (2) | CN121489917A (https=) |
| CA (1) | CA3140046A1 (https=) |
| WO (1) | WO2020232274A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| CN121489917A (zh) * | 2019-05-15 | 2026-02-10 | 贝克森生物医药公司 | 用于皮下注射的氯胺酮制剂 |
| JP7814375B2 (ja) | 2020-08-18 | 2026-02-16 | オークウッド ラボラトリーズ，エル．エル．シー． | ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法 |
| WO2022109050A1 (en) * | 2020-11-18 | 2022-05-27 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds |
| JP2023551145A (ja) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル，インク． | 医薬化合物の錯化剤塩製剤 |
| CA3245931A1 (en) * | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | R-KETAMINE PHARMACEUTICAL FORMULATIONS |
| US20250345458A1 (en) * | 2022-05-18 | 2025-11-13 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios |
| IN202221054235A (https=) | 2022-09-22 | 2023-11-03 | ||
| CN120936348A (zh) * | 2023-02-15 | 2025-11-11 | 克力迈实验室公司 | 任选地与n-酰基乙醇胺组合地包含氯胺酮的组合物及其用途 |
| US12005035B1 (en) * | 2023-08-14 | 2024-06-11 | Daniel C. Javitt | Compositions and methods for treatment of chronic pain and depression |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| WO1997007750A1 (en) * | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration of ketamine to manage pain and to reduce drug dependency |
| ATE367828T1 (de) * | 1998-04-03 | 2007-08-15 | Novartis Vaccines & Diagnostic | Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel |
| CN1172908C (zh) | 1999-12-10 | 2004-10-27 | 中国科学院上海药物研究所 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| AU2004308935A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
| CN1939298A (zh) | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 硫酸舒欣啶固体和靶向制剂及其制备方法 |
| WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| CN101765582A (zh) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| EP3904332B1 (en) * | 2011-10-14 | 2024-12-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| US20130296437A1 (en) | 2012-05-04 | 2013-11-07 | E-Therapeutics Plc | Treatment of Depression |
| US10124940B2 (en) | 2012-09-11 | 2018-11-13 | Zolo Solutions, Inc. | Systems, methods, and devices for dispensing one or more substances |
| WO2017180589A1 (en) | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| CN121489917A (zh) * | 2019-05-15 | 2026-02-10 | 贝克森生物医药公司 | 用于皮下注射的氯胺酮制剂 |
-
2020
- 2020-05-14 CN CN202511966779.7A patent/CN121489917A/zh active Pending
- 2020-05-14 JP JP2021568611A patent/JP2022533971A/ja active Pending
- 2020-05-14 CA CA3140046A patent/CA3140046A1/en active Pending
- 2020-05-14 US US16/874,485 patent/US10973780B2/en active Active
- 2020-05-14 CN CN202080051484.6A patent/CN114126596A/zh active Pending
- 2020-05-14 WO PCT/US2020/032941 patent/WO2020232274A1/en not_active Ceased
- 2020-05-14 EP EP20804815.7A patent/EP3968979A4/en active Pending
-
2021
- 2021-02-26 US US17/187,641 patent/US20210186896A1/en active Pending
-
2025
- 2025-04-03 JP JP2025062046A patent/JP2025114555A/ja active Pending